DNA-Targeted 1,2,4-Benzotriazine 1,4-Dioxides: Potent Analogues of the Hypoxia-Selective Cytotoxin Tirapazamine

Journal of Medicinal Chemistry

Volumn 47, Issue 2, 2004, Pages 475-488

  Hay, Michael P ^a   Pruijn, Frederik B ^a   Gamage, Swarna A ^a   Liyanage, H D Sarath ^a   Kovacs, Mary S ^b   Patterson, Adam V ^a   Wilson, William R ^a   Brown, J Martin ^b   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 BENZOTRIAZINE 1,4 DIOXIDE DERIVATIVE; 4 ACRIDINE CARBOXAMIDE; ACRIDINE DERIVATIVE; BENZOTRIAZOLE DERIVATIVE; CISPLATIN; CYTOTOXIN; DNA; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER; CELL SURVIVAL; CHROMATOPHORE; CLINICAL TRIAL; CLONOGENESIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BINDING; DRUG CYTOTOXICITY; DRUG POTENCY; FATIGUE; GENE TARGETING; HUMAN; HUMAN CELL; HYPOXIA; IC 50; IN VITRO STUDY; IONIC STRENGTH; MOUSE; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PKA; SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; CELL HYPOXIA; CELL LINE, TUMOR; DNA; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INHIBITORY CONCENTRATION 50; MICE; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZINES;

EID: 0347593966     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030399c     Document Type: Article

References (67)

1. Brown, J. M. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumors. Br. J. Cancer 1993, 67, 1163-1170.
2. Denny, W. A.; Wilson, W. R. Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia. Exp. Opin. Invest. Drugs 2000, 9, 2889-2901.
3. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1996, 41, 31-40.
4. Brizel, D. M.; Sibley, G. S.; Prosnitz, L. R.; Scher, R. L.; Dewhirst, M. W. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38, 285-289.
5. Wang, J.; Biedermann, K. A.; Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 1992, 52, 4473-4477.
6. Daniels, J. S.; Gates, K. S.; Tronche, C.; Greenberg, M. M. Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol. 1998, 11, 1254-1257.
7. Anderson, R. F.; Shinde, S. S.; Hay, M. P.; Gamage, S. A.; Denny, W. A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc. 2003, 125, 748-756.
8. Baker, M. A.; Zeman, E. M.; Hirst, V. K.; Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res. 1988, 48, 5947-5952.
9. Wang, J.; Biedermann, K. A.; Wolf, C. R.; Brown, J. M. Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: Enzymatic studies. Brit. J. Cancer 1993, 67, 321-325.
10. Patterson, A. V.; Saunders, M. P.; Chinje, E. C.; Patterson, L. H.; Stratford, I. J. Enzymology of tirapazamine metabolism: A review. Anti-Cancer Drug Des. 1998, 13, 541-573.
11. Delahoussaye, Y. M.; Evans, J. W.; Brown, J. M. Metabolism of tirapazamine by multiple reductases in the nucleus. Biochem. Phamacol. 2001, 62, 1201-1209.
12. Evans, J. W.; Yudoh, K.; Delahoussaye, Y. M.; Brown, J. M. Tirapazamine is metabolized to its DNA damaging radical by intranuclear enzymes. Cancer Res. 1998, 58, 2098-2101.
13. Peters, L. J.; Rischin, D.; Hicks, R. J.; Hughes, P. G.; Sizeland, A. M. Extraordinary tumor control in phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 1999, 45, 148-149.
14. Craighead, P. S.; Pearcey, R.; Stuart, G. A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys. 2000, 48, 791-795.
15. von Pawel, J.; von Roemeling, R.; Gatzemeier, U.; Boyer, M.; Elisson, L. O.; Clark, P.; Talbot, D.; Rey, A.; Butler, T. W.; Hirsh, V.; Olver, I.; Bergman, B.; Ayoub, J.; Richardson, G.; Dunlop, D.; Arcenas, A.; Vescio, R.; Viallet, J.; Treat, J. Tirapazamine plus cisplatin versus cisplatin in advanced nonsmall-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated nonsmall-cell lung tumors. J. Clin. Oncol. 2000, 18, 1351-1359.
16. Del Rowe, J.; Scott, C.; Werner-Wasik, M.; Bahary, J. P.; Curran, W. J.; Urtasun, R. C.; Fisher, B. Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J. Clin. Oncol. 2000, 18, 1254-1259.
17. Rishin, D.; Peters, L.; Hicks, R.; Hughes, P.; Fisher, R.; Hart, R.; Sexton, M.; D'Costa, I.; von Roemeling, R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 535-542.
18. Rauth, A. M.; Melo, T.; Misra, V. Bioreductive therapies: An overview of drugs and their mechanisms of action. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 755-762.
19. Skov, K. A. Workshop report: DNA targeted hypoxic cytotoxins and radiosensitizers. Int. J. Radiat. Biol. 1989, 56, 387-393.
20. Denny, W. A.; Roberts, P. B.; Anderson, R. F.; Brown, J. M.; Wilson, W. R. NLA-1: A 2-nitroimidazole radiosensitizer targeted to DNA by intercalation. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22, 553-556.
21. Cowan, D. S. M.; Matejovic, J. F.; McClelland, R. A.; Rauth, A. M. DNA-targeted 2-nitroimidazoles: In vitro and in vivo studies. Br. J. Cancer 1994, 70, 1067-1074.
22. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)propylamino]cyclopenteno[b]quinoline hydrochloride (NLCPQ-1): A novel DNA-affinic bioreductive agent as chemosensitizer I. Oncol. Res. 1997, 9, 249-257.
23. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive compound as a hypoxia-selective cytotoxin. Oncol. Res. 2001, 12, 185-192.
24. Wilson, W. R.; Denny, W. A.; Twigden, S. J.; Baguley, B. C.; Probert, J. C. Selective cytotoxicity of nitracrine to hypoxic cells. Br. J. Cancer 1984, 49, 215-223.
25. Wilson, W. R.; Siim, B. G.; Denny, W. A.; van Zijl, P. L.; Taylor, M. L. ; Chambers, D. M.; Roberts, P. B. 5-Nitro-4-(N,N-dimethyl-(aminopropyl)amino)quinoline (5-nitroquine), a new DNA affinic hypoxic cell radiosensitizer and bioreductive agent: Comparison with nitracrine. Radiat. Res. 1992, 131, 257-265.
26. Denny, W. A.; Wilson, W. R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic tumour cells. J. Med. Chem. 1986, 29, 879-887.
27. Durand, R. E. Slow penetration of anthracyclines into spheroids and tumors: A therapeutic advantage? Cancer Chemother. Pharmacol. 1990, 26, 198-204.
28. Wilson, W. R.; Denny, W. A. DNA-binding nitroheterocycles as hypoxia-selective cytotoxins. In Radiation Research, a Twentieth-Century Perspective; Dewey, W. C., Edington, M., Fry, R. J. M., Hall, E. J., Whitmore, G. F., Eds; Academic Press: San Diego, 1992; Vol. 2, pp 796-801.
29. Denny, W. A.; Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C. Potential antitumor agents. 49. 5-Substituted derivatives of N-[2-(dimethylamino)ethyl]-9-aminoacridine-4-carboxamide with in vivo solid-tumor activity. J. Med. Chem. 1987, 30, 658-663.
30. Atwell, G. J.; Rewcastle, G. W.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J. Med. Chem. 1987, 30, 664-669.
31. Denny, W. A.; Atwell, G. J.; Baguley, B. C. Minimal DNA-intercalating agents as anti-tumour drugs: 2-Styrylquinoline analogues of amsacrine. Anti-Cancer Drug Des. 1987, 2, 263-270.
32. Rewcastle, G. W.; Denny, W. A.; Baguley, B. C. Potential antitumor agents. 51. Synthesis and antitumor activity of substituted phenazine-1-carboxamides. J. Med. Chem. 1987, 30, 843-851.
33. Palmer, B. D.; Rewcastle, G. W.; Atwell, G. J.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 54. Chromophore requirements for in vivo antitumor activity among the general class of linear tricyclic carboxamides. J. Med. Chem. 1988, 31, 707-712.
34. Atwell, G. J.; Bos, C. D.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 56. "Minimal" DNA-intercalating ligands as antitumor drugs: Phenylquinoline-8-carboxamides. J. Med. Chem. 1988, 31, 1048-1052.
35. Atwell, G. J.; Baguley, B. C.; Denny, W. A. Potential antitumor agents. 57. 2-phenylquinoline-8-carboxamides as "minimal" DNA-intercalating antitumor agents with in vivo solid tumor activity. J. Med. Chem. 1989, 32, 396-401.
36. Hicks, K. O.; Pruijn, F. B.; Baguley, B. C.; Wilson, W. R. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): Diffusion and metabolism in multicellular layers of tumor cells. J. Pharmacol. Exp. Ther. 2001, 297, 1088-1098.
37. McCrystal, M. R.; Evans, B. D.; Harvey, V. J.; Thompson, P. I.; Porter, D. J.; Baguley, B. C. Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. Cancer Chemother. Pharmacol. 1999, 44, 39-44.
38. Twelves, C.; Campone, M.; Coudert, B.; Van den Bent, M.; de Jonge, M.; Dittrich, C.; Rampling, R.; Sorio, R.; Lacombe, D.; de Balincourt, C.; Fumoleau, P. Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme. Ann. Oncol. 2002, 13, 777-780.
39. Papadopoulou, M. V.; Ji, M.; Rao, M. K.; Bloomer, W. D. 4-[3-(2-Nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo: Comparison with tirapazamine. Oncol. Res. 2000, 8, 325-333.
40. Panicucci, R.; Heal, R.; Laderoute, K.; Cowan, D.; McClelland, R. A.; Rauth, A. M. NLP-1: A DNA intercalating hypoxic cell radiosensitizer and cytotoxin. Int. J. Radiat. Oncol. Biol. Phys. 1989, 16, 1039-1043.
41. Cowan, D. S.; Panicucci, R.; McClelland, R. A.; Rauth, A. M. Targeting radiosensitizers to DNA by attachment of an intercalating group: Nitroimidazole-linked phenanthridines. Radiat. Res. 1991, 127, 81-89.
42. Papadopoulou, M. V.; Epperly, M. W.; Shields, D. S.; Bloomer, W. D. Radiosensitization and hypoxic cell toxicity of NLA-1 and NLA-2, two bioreductive compounds. Jpn. J. Cancer Res. 1992, 83, 410-414.
43. Papadopoulou, M. V.; Rosenzweig, H. S.; Doddi, M.; Bloomer, W. D. 9-[3-(2-Nitro-1-imidazolyl)propylamino]-1,2,3,4-tetrahydroacridine hydrochloride. A novel DNA-affinic hypoxic cell cytotoxin and radiosensitizer. Comparison with NLA-1. Oncol. Res. 1994, 6, 439-448.
44. Hicks, K. O.; Pruijn, F. B.; Sturman, J. R.; Denny, W. A.; Wilson, W. R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study using multicellular layer cultures. Cancer Res. 2003, 63, 5970-5977.
45. Jain, R. K. The next frontier of molecular medicine: Delivery of therapeutics. Nat. Med. 1998, 4, 655-657.
46. Tannock, I. F. Tumor physiology and drug resistance. Cancer Metastasis Rev. 2001, 20, 123-132.
47. Delahoussaye, Y. M.; Hay, M. P.; Pruijn, F. B.; Denny, W. A.; Brown, J. M. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem. Pharmacol. 2003, 65, 1807-1815.
48. Robbins, R. F.; Schofield, K. Polyazabicyclic compounds. Part II. Further derivatives of benzo-1,2,4-triazine. J. Chem. Soc. 1957, 3186-3194.
49. Gamage, S. A.; Spicer, J. A.; Rewcastle, G. W.; Denny, W. A. A new synthesis of substituted acridine-4-carboxylic acids and the anticancer drug N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA). Tetrahedron Lett. 1997, 38, 699-702.
50. Corey, E. J.; Nicolaou, K. C.; Balanson, R. D.; Machida, Y. A useful method for the conversion of azides to amines. Synthesis 1975, 590-591.
51. Rolla, F. Sodium borohydride reactions under phase transfer conditions: Reductions of azides to amines. J. Org. Chem. 1982, 47, 4327-4329.
52. Hassner, A.; Levy, L. A. Addition of iodine azide to olefins. Stereospecific introduction of azide functions. J. Am. Chem. Soc. 1965, 87, 4203-4204.
53. Koziara, A.; Zwierzak, A. Optimized procedures for one-pot conversion of alkyl bromides into amines via the Staudinger reaction. Synthesis 1992, 11, 1063-1065.
54. Bayley H.; Standring, D. N.; Knowles, J. R. Propane-1,3-dithiol: A selective reagent for the efficient reduction of alkyl and aryl azides to amines. Tetrahedron Lett. 1978, 39, 3633-3634.
55. Huang, T. L.; Dredar, S. A.; Manneh V. A.; Blankenship, J. W.; Fries, D. S. Inhibition of N8-acetylspermidine deacetylase by active-site-directed metal coordinating inhibitors. J. Med. Chem. 1992, 35, 2414-2418.
56. Siim, B. G.; Hicks, K. O.; Pullen, S. M.; van Zijl, P. L.; Denny, W. A.; Wilson, W. R. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs-Cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem. Pharmacol. 2000, 60, 969-978.
57. Hay, M. P.; Gamage, S. A.; Kovacs, M. S.; Pruijn, F. B.; Anderson, R. F. ; Patterson, A. V.; Wilson, W. R.; Brown, J. M.; Denny, W. A. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 2003, 46, 169-182.
58. Kelson, A. B.; McNamara, J. P.; Pandey, A.; Ryan, K. J.; Dorie, M. J.; McAfee, P. A.; Menke, D. R.; Brown, J. M.; Tracy, M. 1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. Anti-Cancer Drug Des. 1998, 13, 575-592.
59. Crenshaw, J. M.; Graves, D. E.; Denny, W. A. Interactions of acridine antitumor agents with DNA: Binding energies and groove preferences. Biochem. 1995, 34, 13682-13687.
60. Anderson, R. F.; Harris, T. A.; Hay, M. P.; Denny, W. A. Enhanced Conversion of DNA Radical Damage to Double Strand Breaks by 1,2,4-Benzotriazine 1,4-dioxides linked to a DNA Binder compared to Tirapazamine. Chem. Res. Toxicol. 2003, 16, 1477-1483.
61. Durand, R. E.; Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol. Biol. Phys. 1992, 22, 689-692.
62. Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol. Biol. Phys. 1998, 42, 641-649.
63. Kyle, A. H.; Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 1999, 43, 213-220.
64. Mason, J. C.; Tennant, G. Heterocyclic N-oxides. Part VI. Synthesis and nuclear magnetic resonance spectra of 3-amino-benzo-1,2,4-triazines and their mono- and di-N-oxides. J. Chem. Soc. (B) 1970, 911-916.
65. McGhee, J. D.; von Hippel, P. H. Theoretical aspects of DNA-protein interactions: Co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice. J. Mol. Biol. 1974, 86, 469-489.
66. Siim, B. G.; Atwell, G. J.; Wilson, W. R. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br. J. Cancer 1994, 70, 596-603.
67. Wilson, W. R.; Thompson, L. H.; Anderson, R. F., Denny, W. A. Hypoxia-selective antitumor agents. 2. Electronic effects of 4-substituents on the mechanisms of cytotoxicity and metabolic stability of nitracrine analogues. J. Med. Chem. 1989, 32, 31-38.